INVEX Therapeutics Ltd (IXC) - Total Assets
Based on the latest financial reports, INVEX Therapeutics Ltd (IXC) holds total assets worth AU$4.72 Million AUD (≈ $3.34 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See INVEX Therapeutics Ltd (IXC) net assets for net asset value and shareholders' equity analysis.
INVEX Therapeutics Ltd - Total Assets Trend (2019–2025)
This chart illustrates how INVEX Therapeutics Ltd's total assets have evolved over time, based on quarterly financial data.
INVEX Therapeutics Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
INVEX Therapeutics Ltd's total assets of AU$4.72 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 98.3% |
| Accounts Receivable | AU$92.79K | 1.7% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how INVEX Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is INVEX Therapeutics Ltd worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: INVEX Therapeutics Ltd's current assets represent 100.0% of total assets in 2025, an increase from 99.1% in 2019.
- Cash Position: Cash and equivalents constituted 98.3% of total assets in 2025, down from 98.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 1.7% of total assets.
INVEX Therapeutics Ltd Competitors by Total Assets
Key competitors of INVEX Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Ascendis Pharma AS
F:A71
|
Germany | €1.30 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.69 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098
|
China | CN¥1.56 Billion |
INVEX Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 26.76 | 12.22 | 53.07 |
| Quick Ratio | 26.76 | 12.22 | 53.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$4.55 Million | AU$5.38 Million | AU$33.02 Million |
INVEX Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between INVEX Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.52 |
| Latest Market Cap to Assets Ratio | 1.26 |
| Asset Growth Rate (YoY) | -10.7% |
| Total Assets | AU$5.47 Million |
| Market Capitalization | $6.91 Million USD |
Valuation Analysis
Above Book Valuation: The market values INVEX Therapeutics Ltd's assets above their book value (1.26x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: INVEX Therapeutics Ltd's assets decreased by 10.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for INVEX Therapeutics Ltd (2019–2025)
The table below shows the annual total assets of INVEX Therapeutics Ltd from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$5.47 Million ≈ $3.87 Million |
-10.66% |
| 2024-06-30 | AU$6.12 Million ≈ $4.33 Million |
-73.16% |
| 2023-06-30 | AU$22.80 Million ≈ $16.14 Million |
-22.66% |
| 2022-06-30 | AU$29.49 Million ≈ $20.86 Million |
-9.93% |
| 2021-06-30 | AU$32.74 Million ≈ $23.16 Million |
+23.92% |
| 2020-06-30 | AU$26.42 Million ≈ $18.69 Million |
+113.49% |
| 2019-06-30 | AU$12.37 Million ≈ $8.76 Million |
-- |
About INVEX Therapeutics Ltd
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II… Read more